Core Viewpoint - Capricor Therapeutics has announced a proposed underwritten public offering of its common stock to support the development of its product candidates and general corporate purposes [1][2]. Group 1: Offering Details - The public offering includes a 30-day option for underwriters to purchase an additional 15% of the shares sold [1]. - The offering is subject to market conditions, and there is no assurance regarding its completion or terms [1]. - The securities are being offered under an effective shelf registration statement filed with the SEC [3]. Group 2: Use of Proceeds - The net proceeds from the offering will be used for the continued development and manufacturing of product candidates, working capital, and general corporate purposes [2]. Group 3: Company Overview - Capricor Therapeutics focuses on cell and exosome-based therapeutics for rare diseases, with its lead product candidate, deramiocel (CAP-1002), in Phase 3 clinical development for Duchenne muscular dystrophy [5]. - The company utilizes its proprietary StealthX™ platform for exosome technology aimed at various therapeutic applications [5]. - Capricor has an exclusive commercialization agreement for deramiocel in the U.S. and Japan with Nippon Shinyaku Co., Ltd., pending regulatory approval [8].

Most of us have heard the dictum "the trend is your friend." And this is undeniably the key to success when it comes to short-term investing or trading. But it isn't easy to ensure the sustainability of a trend and profit from it. The trend often reverses before exiting the trade, leading to a short-term capital loss for investors. So, for a profitable trade, one should confirm factors such as sound fundamentals, positive earnings estimate revisions, etc. that could keep the momentum in the stock alive. Inv ...

Core Viewpoint - Capricor Therapeutics has initiated a rolling submission process for a Biologics License Application (BLA) for deramiocel, aimed at treating Duchenne muscular dystrophy (DMD) cardiomyopathy, with plans to complete the submission by the end of 2024 and potential eligibility for priority review by the FDA [1][2]. Group 1: Company Overview - Capricor Therapeutics is a biotechnology company focused on developing cell and exosome-based therapeutics for rare diseases, with deramiocel (CAP-1002) as its lead product candidate [6]. - The company has entered into an exclusive commercialization agreement for deramiocel in the U.S. and Japan with Nippon Shinyaku Co., Ltd., pending regulatory approval [9]. Group 2: Product Details - Deramiocel consists of allogeneic cardiosphere-derived cells (CDCs) that have shown immunomodulatory, antifibrotic, and regenerative effects in preclinical and clinical studies [3]. - The product has received Orphan Drug Designation and is supported by the Regenerative Medicine Advanced Therapy (RMAT) designation [4]. Group 3: Disease Context - Duchenne muscular dystrophy (DMD) is a severe genetic disorder affecting approximately 15,000-20,000 individuals in the U.S., characterized by progressive muscle weakness and inflammation, with a median mortality age of around 30 years [5]. - There are currently no approved treatment options for DMD cardiomyopathy, highlighting the significance of deramiocel as a potential first-in-class therapy [2][5].

Capricor Therapeutics (CAPR) closed the last trading session at $18.09, gaining 330.7% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $34.40 indicates a 90.2% upside potential. The average comprises five short-term price targets ranging from a low of $25 to a high of $43, with a standard deviation of $8.71. While the lowest estimate indicates an increase of 38.2% from the current ...

Capricor Therapeutics Inc. CAPR is a biotechnology firm focused on developing cell and exosome-based treatments for rare diseases like Duchenne muscular dystrophy (DMD). Capricor's stock surged more than 100% after announcing it will pursue full FDA approval for its primary drug deramiocel (CAP-1002) in this year. The medical sector company plans to file the biologics license application (BLA) in October 2024, seeking full FDA approval to treat all patients with cardiomyopathy associated with DMD. This rare ...

Capricor Therapeutics Inc. NASDAQ: CAPR is a biotechnology firm focused on developing cell and exosome-based treatments for rare diseases like Duchenne muscular dystrophy (DMD). Capricor's stock surged more than 100% after announcing it will pursue full FDA approval for its primary drug deramiocel (CAP-1002) in this year. The medical sector company plans to file the biologics license application (BLA) in October 2024, seeking full FDA approval to treat all patients with cardiomyopathy associated with DMD. C ...

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

Capricor Therapeutics (CAPR) shares rallied 18.2% in the last trading session to close at $5.97. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 10.8% gain over the past four weeks. The sharp upsurge in Capricor's shares can be attributed to the company's anticipated regulatory update on deramiocel for Duchenne muscular dystrophy (DMD) in an investor webcast scheduled for Sept. 24. The webcast will include th ...

SAN DIEGO, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that it will host an investor webcast on Tuesday, September 24, 2024 at 8:30 a.m. ET to provide an update on its Duchenne muscular dystrophy (DMD) program. The update will consist of the latest regulatory updates following the Company's recent meetings with the U.S. Food and Drug Administr ...

-Capricor to Receive $15 Million Equity Investment at a 20% Premium, as well as $20 Million Upfront Payment upon Signing Definitive Agreement with up to $715 Million in Potential Milestones and a DoubleDigit Percentage of Product Revenue- -Upfront Payment and Investment Extends Cash Runway into 2026- -Potential Milestones from Combined Distribution Agreements Now Total approximately $1.5 Billion- -Capricor Preparing to Meet with EMA to Discuss European Expansion for Deramiocel- SAN DIEGO, Sept. 17, 2024 (GL ...